A Retrospective Review and Observational Study of Outcomes and Safety of Bimatoprost Ophthalmic Solution 0.03% for Treating Eyelash Hypotrichosis

• Published in: Dermatologic surgery Vol. 40; no. 10; pp. 1118 - 1124
• Main Authors: Yoelin, Steven G, Fagien, Steven, Cox, Sue Ellen, Davis, Paula G, Campo, Antoinette, Caulkins, Carrie A, Gallagher, Conor J
• Format: Journal Article
• Language: English
• Published: United States by the American Society for Dermatologic Surgery, Inc. Published by Lippincott Williams & Wilkins 01-10-2014
• Subjects: Adult; Amides - adverse effects; Amides - therapeutic use; Bimatoprost; Cloprostenol - adverse effects; Cloprostenol - analogs & derivatives; Cloprostenol - therapeutic use; Cross-Sectional Studies; Erythema - chemically induced; Eyelashes; Eyelid Diseases - chemically induced; Female; Humans; Hypotrichosis - drug therapy; Male; Middle Aged; Ophthalmic Solutions - adverse effects; Ophthalmic Solutions - therapeutic use; Patient Satisfaction; Pigmentation Disorders - chemically induced; Pruritus - chemically induced; Retrospective Studies; Treatment Outcome
• ISSN: 1076-0512; 1524-4725
• DOI: 10.1097/01.DSS.0000452658.83001.d9

BACKGROUNDThe efficacy and safety of bimatoprost ophthalmic solution 0.03% for treating hypotrichosis were shown in a randomized controlled trial and in an open-label study. To date, no data on real-world experience have been published.
OBJECTIVETo evaluate long-term patient satisfaction, usage patterns, and safety of bimatoprost 0.03% in clinical practice.
MATERIALS AND METHODSIn this retrospective chart review with a cross-sectional design, adult patients exposed to bimatoprost 0.03% for at least 12 months were randomly sampled from 16 investigational sites. Charts were reviewed for medication usage characteristics and adverse events (AEs). At a study visit, questionnaires eliciting patient-reported outcomes were administered and spontaneously reported AEs were tabulated.
RESULTSAnalysis included 585 subjects with a mean (SD) treatment duration of 19.3 (4.3) months. Patient satisfaction with bimatoprost 0.03% was 92.5%; on average, approximately 3 applications per week maintained benefits. Overall, 27.4% of patients spontaneously recalled experiencing AEs while on treatment; however, patient charts showed that only 4 AEs were documented. No instances of iris hyperpigmentation occurred. No serious or severe AEs were noted.
CONCLUSIONTreatment with bimatoprost 0.03% for at least 12 months is safe, and long-term use is associated with a high degree of satisfaction.